China has mastered the technology for producing Yttrium-90, an isotope used in radiation therapy, in commercial reactors, the China National Nuclear Corporation (CNNC) revealed on Sunday.
The Yttrium-90 glass microspheres irradiated in a reactor at the CNNC's Qinshan Nuclear Power Base in Zhejiang Province have passed all relevant tests, paving the way for mass production.
Yttrium-90 glass microspheres are mainly made from Yttrium-89, which turns into radioactive Yttrium-90 after absorbing neutrons in a nuclear reactor.
These microspheres are used as a radioactive drug that releases beta radiation. By using vascular intervention techniques, the Yttrium-90 microspheres are delivered to the liver's blood vessels to treat liver tumors, making it a minimally invasive procedure.
Experts revealed that once out of the reactor, the Yttrium-90 produced is to be thoroughly examined by researchers before entering the application stage.
The commercial heavy-water reactor at the Qinshan Nuclear Power Base offers unique advantages for producing Yttrium-90, according to engineers.
"The commercial heavy-water reactor has a relatively high neutron flux, and it is able to operate stably. The activation zone of the core is very big. Using this type of reactor to produce Yttrium-90 has significant benefits, such as the ability to increase production, reduce costs, and provide a consistent supply," said Li Shisheng, deputy chief engineer at the Qinshan Nuclear Power Base.
China successfully produces Yttrium-90 in commercial reactors
China successfully produces Yttrium-90 in commercial reactors
